Literature DB >> 7749688

Mesocaval interposition shunt with small-diameter polytetrafluoroethylene grafts in sclerotherapy failure.

K J Paquet1, A Lazar, P Koussouris, B Hotzel, H A Gad, R Kuhn, J F Kalk.   

Abstract

Fifty-seven patients with failed sclerotherapy received a mesocaval interposition shunt with an externally supported, ringed polytetrafluoroethylene prosthesis of either 10 or 12 mm diameter. Thirty-one patients had Child-Pugh grade A disease and 26 grade B; all had a liver volume of 1000-2500 ml. Follow-up ranged from 16 months to 6 years 3 months. Three patients (5 per cent) died in the postoperative period. There were two postoperative recurrences of variceal haemorrhage and one recurrent bleed in the second year after surgery. The cumulative shunt patency rate was 95 per cent and the incidence of encephalopathy 9 per cent; the latter was successfully managed by protein restriction and/or lactulose therapy. The actuarial survival rate for the whole group at 6 years was 78 per cent, for those with Child-Pugh grade A 88 per cent and for grade B 67 per cent. Small-lumen mesocaval interposition shunting achieves portal decompression, preserves hepatopetal flow, has a low incidence of shunt thrombosis, prevents recurrent variceal bleeding and is not associated with significant postoperative encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749688     DOI: 10.1002/bjs.1800820219

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

Review 1.  Psychiatric aspects of portal-systemic encephalopathy.

Authors:  J Wiltfang; W Nolte; K Weissenborn; J Kornhuber; E Rüther
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

2.  Should stent-grafts replace bare stents for primary transjugular intrahepatic portosystemic shunts?

Authors:  Manfred Cejna
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

3.  Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.

Authors:  J Wiltfang; W Nolte; M Otto; J Wildberg; E Bahn; H R Figulla; L Pralle; H Hartmann; E Rüther; G Ramadori
Journal:  Metab Brain Dis       Date:  1999-12       Impact factor: 3.584

Review 4.  Current state of portosystemic shunt surgery.

Authors:  Martin Wolff; Andreas Hirner
Journal:  Langenbecks Arch Surg       Date:  2003-03-29       Impact factor: 3.445

5.  Hepatic encephalopathy verified by psychometric testing and EEG in cirrhotic patients: effects of mesocaval interposition shunt or sclerotherapy.

Authors:  B Isaksson; L-H Thorell; F Bengtsson; I Rosén; B Jeppsson
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 6.  Update on Shunt Surgery.

Authors:  Tim R Glowka; Jörg C Kalff; Steffen Manekeller
Journal:  Visc Med       Date:  2020-04-14

7.  Duodenal Erosion and Obstruction Caused by a Mesocaval Prosthesis.

Authors:  Junjie Liu; Shi Chen; Jun Xiang; Junsheng Peng
Journal:  ACG Case Rep J       Date:  2019-06-17

Review 8.  Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View.

Authors:  Tim R Glowka; Jörg C Kalff; Nico Schäfer
Journal:  Viszeralmedizin       Date:  2014-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.